Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011

Diabetes Care

Volumn 39, Issue 3, 2016, Pages 363-370

  Pathak, Ram D ^a   Schroeder, Emily B ^b   Seaquist, Elizabeth R ^c   Zeng, Chan ^b   Lafata, Jennifer Elston ^d,e   Thomas, Abraham ^e   Desai, Jay ^f   Waitzfelder, Beth ^b   Nichols, Gregory A ^b   Lawrence, Jean M ^b   Karter, Andrew J ^b   Steiner, John F ^b   Segal, Jodi ^g   O'Connor, Patrick J ^f  

^a MARSHFIELD CLINIC   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f HEALTHPARTNERS INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; GLUCOSE BLOOD LEVEL;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HEALTH CARE DELIVERY; HUMAN; HYPOGLYCEMIA; ICD-9; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; SEX; UNITED STATES; AGED; ANALYSIS; BLOOD; DISEASE MANAGEMENT; GLUCOSE BLOOD LEVEL; INTEGRATED HEALTH CARE SYSTEM; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; AGED; BLOOD GLUCOSE; COHORT STUDIES; COMORBIDITY; DELIVERY OF HEALTH CARE, INTEGRATED; DIABETES MELLITUS; DISEASE MANAGEMENT; FEMALE; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84962077682     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0858     Document Type: Article

References (46)

1. American Diabetes Association. Standards of medical care in diabetesd2013. Diabetes Care 2013;36(Suppl. 1):S11-S66
2. The Diabetes Control and Complications Trial Research Group. The effectof intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
3. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998;352:832-833
4. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sul-phonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. American Diabetes Association. Standards of medical care for patientswith diabetes mellitus. Diabetes Care 1994;17:616-623
7. American Diabetes Association. Standards of medical care for patientswith diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):S33-S50
8. Blumenthal KJ, Larkin ME, Winning G, Nathan DM, Grant RW. Changes in glycemic control from 1996 to 2006 among adults with type 2 diabetes: a longitudinal cohort study. BMC Health Serv Res 2010;10:158
9. Nguyen NT, Nguyen XM, Lane J, Wang P. Relationship between obesity and diabetes in a US adult population: findings from the National Health and Nutrition Examination Survey, 1999-2006. Obes Surg 2011;21:351-355
10. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376: 419-430
11. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572
12. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139
13. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
14. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
15. Chew EY, Ambrosius WT, Davis MD, et al.; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinop-athy progression in type 2 diabetes. N Engl J Med 2010;363:233-244
16. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009;52:2288-2298
17. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-422
18. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559
19. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab 2012;97:41-48
20. Ma J, Yang W, Fang N, Zhu W, Wei M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. Nutr Metab Cardio-vasc Dis 2009;19:596-603
21. Lee SJ. So much insulin, so much hypogly-cemia. JAMA Intern Med 2014;174:686-688
22. Laiteerapong N, Karter AJ, Liu JY, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care 2011;34:1749-1753
23. Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hypergly-cemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014;174:1116-1124
24. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
25. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care 2013;36:3535-3542
26. Quilliam BJ, Simeone JC, Ozbay AB, Kogut SJ. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care 2011;17: 673-680
27. Geller AI, Shehab N, Lovegrove MC, et al. National estimates of insulin-related hypoglyce-mia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014;174:678-686
28. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2015;38:22-28
29. Mellbin LG, Malmberg K, Waldenström A, Wedel H, Rydén L. DIGAMI 2investigators. Prognostic implications of hypoglcaemic episodes during hospitalization for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial. Heart 2009;95:721-727
30. Nichols GA, Desai J, Elston Lafata J, et al.; SUPREME-DM Study Group. Construction of a multisite DataLink using electronic health records for the identification, surveillance, prevention, and management of diabetes mellitus: the SUPREME-DM project. Prev Chronic Dis 2012;9:E110
31. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypo-glycemia visits. BMC Endocr Disord 2008;8:4
32. Centers for Disease Controland Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014
33. O'Connor PJ, Rush WA, Peterson J, et al. Continuous quality improvement can improve glycemic control for HMO patients with diabetes. Arch Fam Med 1996;5:502-506
34. Go AS, Magid DJ, Wells B, et al. The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research. Circ Cardiovasc Qual Outcomes 2008;1:138-147
35. Whitmer RA, Karter AJ, YaffeK, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009;301:1565-1572
36. Raebel MA, Ellis JL, Schroeder EB, et al. Intensification of antihyperglycemic therapy among patients with incident diabetes: a Surveillance Prevention and Management of Diabetes Mellitus (SUPREME-DM) study. Phar-macoepidemiol Drug Saf 2014;23:699-710
37. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-682
38. Wright AD, Cull CA, Macleod KM, Holman RR; UKPDS Group. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, met-formin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20: 395-401
39. Seaquist ER, Anderson J, Childs B, et al. Hy-poglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384-1395
40. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005;28:2948-2961
41. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med 2014;174:251-258
42. Katon WJ, Young BA, Russo J, et al. Association of depression with increased risk of severe hypoglycemic episodes in patients with diabetes. Ann Fam Med 2013;11:245-250
43. Fox CS,Golden SH, Anderson C, et al.;Amer-ican Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research, and the American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015;132: 691-718
44. Elwen FR, Huskinson A, Clapham L, et al. An observational study of patient characteristics and mortality following hypoglycemia in the community. BMJ Open Diabetes Res Care 2015;3:e000094
45. Zoungas S, Patel A, Chalmers J, et al.; ADVANCE Collaborative Group. Severe hypogly-cemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418
46. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med 2001;250:11-17